Why the study?
Does adriamycin induce objective tumor responses in patients with solid and hematologic malignancies?
Does adriamycin induce objective tumor responses in patients with solid and hematologic malignancies?
Adriamycin is an effective antineoplastic agent for various solid and hematologic malignancies, though its use is associated with dose-limiting hematologic and cardiac toxicities.
Supports historical efficacy with toxicity limits; leaves open modern comparative trials.
Adriamycin, a new antineoplastic drug, induces objective tumor responses in solid tumors (adenocarcinoma of the breast, malignant sarcomas, bronchogenic carcinoma, and neuroblastoma) as well as in hematologic malignancies (malignant lymphomas and acute leukemia). The responses in specific tumor types are reviewed, and the relative clinical efficacy of adriamycin is compared with that of other antitumor agents. The toxic effects of adriamycin are also reviewed. Adriamycin therapy results in dose-limiting hematologic and cardiac toxicity, as well as stomatitis, nausea, vomiting, and alopecia, but in general these toxicities are predictable and reversible. The theoretical limitations of this type of review are pointed out.
No takes yet. Share an insight, caveat, or question.
Ronald H. Blum (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: